Normunity Doses First Patient with Novel T Cell Engager NRM-823 in Phase 1 Solid Tumor Trial
核心洞察
Normunity (搜索) has dosed the first patient in a Phase 1 clinical trial of NRM-823 (搜索), a first-in-class T cell engager targeting a novel tumor-specific antigen in solid tumors (搜索).
The Phase 1a/1b study will evaluate NRM-823 (搜索) as monotherapy and in combination with immune checkpoint inhibitors (搜索) in patients with locally-advanced or metastatic refractory solid tumors (搜索).
Preclinical data demonstrated potent anti-tumor activity with T cell-mediated cytotoxicity in humanized mouse models and favorable safety profile in non-human primates.
Normunity (搜索), a biotechnology company pioneering precision biologics, has achieved a significant milestone by dosing the first patient in a Phase 1 clinical trial for NRM-823 (搜索), a first-in-class T cell engager targeting a novel immuno-active tumor-specific antigen. The trial (NCT07182149) marks the company's transition to clinical-stage operations and represents a potentially transformational approach to cancer (搜索) immunotherapy.
Novel Target and Mechanism of Action
NRM-823 (搜索) represents a new class of T cell engagers designed to harness the body's immune system by activating and redirecting T cells (搜索) to precisely target tumor cells (搜索). The therapy addresses what Normunity (搜索) describes as an "immuno-active novel target" that is homogeneously and commonly expressed across a broad range of solid tumors (搜索) while being absent in normal systemic tissues.
"This study is the initial step utilizing our first in a new class of Immuno-smart targets for our T cell engager, NRM-823 (搜索), and we plan to leverage this target in broader therapeutic modalities beyond T cell engagers," said Rachel Humphrey, MD, Chief Executive Officer of Normunity (搜索). "We believe that NRM-823 exemplifies the power of our proprietary discovery platform to uncover new biologic insights specific to both the immune system and tumors."
Clinical Trial Design and Patient Population
The Phase 1a/1b study is designed to evaluate the safety, tolerability, and initial efficacy of NRM-823 (搜索) in increasing dose levels. The trial will assess the therapy both as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastatic refractory solid tumors (搜索) that express the relevant target.
Melinda Merchant, MD, PhD, Chief Medical Officer of Normunity (搜索), emphasized the clinical rationale: "Our team is particularly encouraged by the ability of NRM-823 (搜索) to address a previously unrecognized target that appears to support cancer (搜索) survival across a range of solid tumor indications."
Preclinical Efficacy and Safety Profile
The transition to clinical testing is supported by compelling preclinical data demonstrating NRM-823 (搜索)'s therapeutic potential. In vitro and in vivo studies showed potent anti-tumor activity with T cell-mediated cytotoxicity in humanized mouse models across multiple cancer (搜索) types.
Safety assessments have been equally encouraging, with NRM-823 (搜索) demonstrating a favorable pharmacokinetic and preclinical safety profile. Notably, the GLP toxicity study in non-human primates showed no observed adverse events at the highest dose tested, which was supratherapeutic levels.
"The compelling preclinical efficacy and safety data give us confidence to move into the clinic to evaluate the potential of NRM-823 (搜索) for patients with advanced or metastatic solid tumors (搜索)," Merchant stated.
Platform Technology and Pipeline Development
Normunity (搜索)'s approach centers on identifying "Immuno-smart targets" responsible for tumor-specific immune suppression through their proprietary target discovery platform. The company focuses on untapped biology at the interface of the immune system and tumors, using these novel targets to build a comprehensive pipeline of anti-cancer (搜索) medicines.
Beyond T cell engagers, the company's platform enables development of therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. This diversified approach positions NRM-823 (搜索) as the first of potentially multiple therapeutics targeting the same novel antigen across different modalities.
The initiation of this Phase 1 trial represents what Humphrey describes as "an important milestone for Normunity (搜索), as we bring a potentially transformational cancer (搜索) therapy forward to patients and transition to a clinical-stage company."